The Pandemic Speeds Up the Health-Care Revolution
The drive to quickly conquer Covid-19 has accelerated innovation across the health-care sector. Barron’s roundtable experts highlight the most promising... · 1d ago
FibroGen (FGEN) Investor Presentation - Slideshow
The following slide deck was published by FibroGen, Inc. in conjunction with this event.
Seekingalpha · 09/18 17:39
Market Sentiment Around Loss-Making FibroGen, Inc. (NASDAQ:FGEN)
We feel now is a pretty good time to analyse FibroGen, Inc.'s (NASDAQ:FGEN) business as it appears the company may be...
Simply Wall St. · 09/15 12:31
The Daily Biotech Pulse: AbbVie In-licenses I-Mab's Cancer Drug, Savara Pulls The Plug On Cystic Fibrosis Study
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 3)
Benzinga · 09/04 11:28
Akebia's vadadustat pain is FibroGen's gain, up 15%
FibroGen (FGEN) is up 15% premarket on average volume in apparent response to the selloff in Akebia Therapeutics (AKBA) after it reported that two late-studies evaluating vadadustat in non-dialysis patients with CKD
Seekingalpha · 09/03 13:18
FibroGen to Present at Upcoming Investor Conferences
SAN FRANCISCO, Sept. 01, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) today announced that Enrique Conterno, Chief Executive Officer, will participate in fireside chats at the following virtual healthcare conferences: * Citigroup 15th Annual BioPharma Conference on September 9, 2020 at 2
GlobeNewswire · 09/01 12:00
FibroGen Announces First Patient Enrolled In Pamrevlumab Phase 3 Clinical Trial In Patients With Duchenne Muscular Dystrophy
SAN FRANCISCO, Aug. 11, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ:FGEN) announced the initiation of LELANTOS, a Phase 3, randomized, double-blind, placebo-controlled trial of pamrevlumab orplacebo in combination
Benzinga · 08/11 11:06
FibroGen EPS misses by $0.39, misses on revenue
FibroGen (NASDAQ:FGEN): Q2 GAAP EPS of -$0.95 misses by $0.39. Revenue of $42.89M (-77.6% Y/Y) misses by $5.4M. Press Release
seekingalpha · 08/07 01:40
Earnings Preview: FibroGen (FGEN) Q2 Earnings Expected to Decline
FibroGen (FGEN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 07/30 16:33
FibroGen to Report Second Quarter 2020 Financial Results
SAN FRANCISCO, July 23, 2020 (GLOBE NEWSWIRE) -- FibroGen, Inc. (NASDAQ: FGEN) will announce its second quarter 2020 financial results on Thursday, August 6 after the market close. FibroGen will also conduct a conference call on that day at 5:00 p.m. ET (2:00
GlobeNewswire · 07/23 11:00
Did Hedge Funds Make The Right Call On FibroGen Inc (FGEN) ?
The latest 13F reporting period has come and gone, and Insider Monkey have plowed through 821 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of
Insider Monkey · 07/17 19:31
FibroGen Begins Phase II Study for Acute Coronavirus in US
Zacks · 06/24 17:00
Sarepta Addressing Gene Therapy Issue With Two Acquisitions · 06/23 21:05
FibroGen enrolls first patient in pamrevlumab trial for COVID-19
Seeking Alpha - Article · 06/23 13:05
FibroGen Announces First Patient Enrolled in Pamrevlumab Clinical Trial in Patients Hospitalized in U.S. with Acute COVID-19
GlobeNewswire · 06/23 12:00
FibroGen Appoints Thane Wettig as Chief Commercial Officer
GlobeNewswire · 06/22 12:00
Hedge Funds Are Nibbling On FibroGen Inc (FGEN)
Insider Monkey · 06/16 14:20
Weekly CEO Buys Highlight: Camping World, FibroGen · 06/15 15:42
FibroGen (FGEN) in Focus: Stock Moves 6.5% Higher
Zacks · 06/11 01:37
FibroGen Initiates Phase II/III Study in Severe Coronavirus
Zacks · 06/09 15:17
Webull provides a variety of real-time FGEN stock news. You can receive the latest news about FibroGen through multiple platforms. This information may help you make smarter investment decisions.
About FGEN
FibroGen, Inc. is a science-based biopharmaceutical company discovering and developing a pipeline of first- in-class therapeutics. The Company is focused on fibrosis and hypoxia-inducible factor (HIF) biology and clinical development to advance innovative medicines for the treatment of anemia, fibrotic disease, and cancer. Roxadustat, the Company’s most advanced product candidate, is an oral small molecule inhibitor of HIF prolyl hydroxylase activity in Phase III clinical development for the treatment of anemia in chronic kidney disease (CKD), and is entering Phase III development for anemia in lower risk myelodysplastic syndromes (MDS). The Company has developed Pamrevlumab. Pamrevlumab is a proprietary therapeutic antibody to inhibit the activity of connective tissue growth factor (CTGF), a common factor in chronic fibrotic and proliferative disorders characterized by persistent and excessive scarring that can lead to organ dysfunction and failure.